Skip to main content
. 2020 Mar 11;12(4):e11298. doi: 10.15252/emmm.201911298

Figure 2. Engineering of a bivalent KB‐AT‐23 sdAb and test of its antithrombin inhibitory activity in vitro .

Figure 2

  • A
    Schematic representation of the bivalent KB‐AT‐23 sdAb.
  • B, C
    Graphs reporting the recovery of thrombin‐ and FXa‐mediated substrate conversion in the presence of increasing doses of KB‐AT‐23, in the presence of antithrombin and heparin. Data represent mean ± SD of three experiments.
  • D, E
    Thrombin generation profiles of FVIII‐deficient plasma spiked with different concentrations of recombinant FVIII or 2 doses of KB‐AT‐23. Data are representative thrombograms. Detailed information on thrombin generation parameters is provided in Table 2. Antithrombin activity was inhibited by 81.1 ± 6.1% and 54.1 ± 8.4% for the 0.2 and 0.1 mg/ml concentration, respectively.